Virtu Financial’s Niagen Bioscience NAGE Stock Holding History

Virtu Financial’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-12,749	Closed	-$68K	–	2197
2024 Q4	$68K	Buy	+12,749	New	+$69.8K	﹤0.01%	1104
2023 Q2	–	Sell	-17,377	Closed	-$27K	–	2156
2023 Q1	$27K	Buy	+17,377	New	+$30.9K	﹤0.01%	1191
2022 Q3	–	Sell	-45,455	Closed	-$76K	–	2331
2022 Q2	$76K	Buy	+45,455	New	+$88.9K	0.01%	1005
2019 Q4	–	Sell	-18,155	Closed	-$71K	–	1935
2019 Q3	$71K	Buy	+18,155	New	+$77.4K	0.01%	1141
2017 Q4	–	Sell	-63,189	Closed	-$272K	–	3120
2017 Q3	$272K	Buy	+63,189	New	+$231K	0.01%	1488

Other funds holding NAGE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Virtu Financial's NAGE Position: Q1 2025 in Review

Virtu Financial sold out of Niagen Bioscience (NAGE) in Q1 2025, closing a stake of 12,749 shares — an estimated $68K sold.

Virtu Financial first reported a position in NAGE in Q3 2017 and held it in 5 quarters. The position peaked at $272K in Q3 2017. 139 funds tracked by Wall St. Rank hold NAGE as of Q1 2025.

Virtu Financial reported no remaining Niagen Bioscience position as of Q1 2025 after selling out during the quarter.
Virtu Financial sold 12,749 Niagen Bioscience shares in Q1 2025, an estimated $68K.
Virtu Financial first reported a position in Niagen Bioscience in Q3 2017 and held it in 5 quarters.
Virtu Financial's Niagen Bioscience position peaked at $272K in Q3 2017.
139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2025.

Based on Virtu Financial's 13F filing for Q1 2025, filed 12 May 2025.